KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Deferred Taxes: 2017-2019

Historic Deferred Taxes for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2019 value amounting to $33,000.

  • Amneal Pharmaceuticals' Deferred Taxes rose 110.06% to $33,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $371.7 million, marking a year-over-year increase of 4038.09%. This contributed to the annual value of $371.7 million for FY2019, which is 4038.09% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Deferred Taxes stood at $33,000 for Q4 2019, which was down 99.99% from $389.9 million recorded in Q3 2019.
  • In the past 5 years, Amneal Pharmaceuticals' Deferred Taxes registered a high of $389.9 million during Q3 2019, and its lowest value of -$14.5 million during Q2 2018.
  • Over the past 3 years, Amneal Pharmaceuticals' median Deferred Taxes value was -$420,000 (recorded in 2018), while the average stood at $36.3 million.
  • Data for Amneal Pharmaceuticals' Deferred Taxes shows a peak YoY increase of 6,528.56% (in 2019) and a maximum YoY decrease of 1,830.47% (in 2019) over the last 5 years.
  • Over the past 3 years, Amneal Pharmaceuticals' Deferred Taxes (Quarterly) stood at $1.3 million in 2017, then tumbled by 125.71% to -$328,000 in 2018, then surged by 110.06% to $33,000 in 2019.
  • Its Deferred Taxes stands at $33,000 for Q4 2019, versus $389.9 million for Q3 2019 and -$8.3 million for Q2 2019.